Accounting for uncertainty in the historical response rate of the standard treatment in single‐arm two‐stage designs based on Bayesian power functions

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Pharmaceutical statistics

• Publication date

  Unknown publication date

• Fields of study

  Mathematics, Medicine, Computer Science

• Identifiers
  DOI 10.1002/pst.1788PMID 27766770
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized Phase II Cancer Clinical Trials, Sin-Ho Jung著, CRC Press, 2013年3月, 244 pp., 価格 £57.99, ISBN 978-1439871850

  2015influential reference
• A randomized two‐stage design for phase II clinical trials based on a Bayesian predictive approach

  2015cited by this paper
• Sample size planning for phase II trials based on success probabilities for phase III

  2015cited by this paper
• Use of historical control data for assessing treatment effects in clinical trials

  2014cited by this paper
• A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation

  2014cited by this paper
• On the Limiting Behavior of the “Probability of Claiming Superiority” in a Bayesian Context

  2013cited by this paper
• Clinical Trial Design: Bayesian and Frequentist Adaptive Methods by YIN, G

  2012cited by this paper
• A Bayesian–frequentist two‐stage single‐arm phase II clinical trial design

  2012cited by this paper
• Randomized phase II trials: a long-term investment with promising returns.

  2011cited by this paper
• Effect of a misspecification of response rates on type I and type II errors, in a phase II Simon design.

  2011cited by this paper
• A Bayesian predictive strategy for an adaptive two‐stage design in phase II clinical trials

  2010cited by this paper
• Randomized phase II trials: inevitable or inadvisable?

  2010cited by this paper
• Applied categorical data analysis and translational research

  2010cited by this paper
• Optimising the design of phase II oncology trials: the importance of randomisation.

  2009cited by this paper
• Classical and Bayesian power functions; their use in clinical trials.

  2008cited by this paper
• A Bayesian predictive two‐stage design for phase II clinical trials

  2008cited by this paper
• Randomized phase II trials with a prospective control

  2008influential reference
• Robust Bayesian sample size determination in clinical trials

  2008cited by this paper
• Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

  2007cited by this paper
• Adaptive two‐stage designs in phase II clinical trials

  2006cited by this paper
• Bayesian two‐stage designs for phase II clinical trials by S. B. Tan and D. Machin, Statistics in Medicine 2002; 21:1991–2012

  2006cited by this paper
• A Bayesian method of sample size determination with practical applications

  2006cited by this paper
• Sample Size Determination for Robust Bayesian Analysis

  2006cited by this paper
• A design of phase II cancer trials using total and complete response endpoints

  2005cited by this paper
• Bayesian designs with frequentist and Bayesian error rate considerations

  2005cited by this paper
• Adaptive Two‐Stage Designs for Single‐Arm Phase IIA Cancer Clinical Trials

  2004cited by this paper
• Bayesian Approaches to Clinical Trials and Health-Care Evaluation: Spiegelhalter/Clinical Trials and Health-Care Evaluation

  2004cited by this paper
• A simulation-based approach to Bayesian sample size determination for performance under a given model and for separating models

  2002cited by this paper
• Optimal three-stage designs for phase II cancer clinical trials.

  1997cited by this paper
• Bivariate sequential designs for phase II trials.

  1995cited by this paper
• Incorporating toxicity considerations into the design of two-stage phase II clinical trials.

  1995cited by this paper
• Practical Bayesian guidelines for phase IIB clinical trials.

  1994influential reference
• Optimal two-stage designs for phase II clinical trials.

  1989influential reference

• Statistical methodologies for absolute and relative efficacy assessment based on single-arm trials: a scoping review.

  2026cites this paper
• On the Interpretation and the Choice of the Hyperparameters of a Beta Prior Distribution

  2025cites this paper
• Hybrid classical-Bayesian approach to sample size determination for two-arm superiority clinical trials

  2024cites this paper
• Frequentist and Bayesian Sample Size Determination for Single-Arm Clinical Trials Based on a Binary Response Variable: A Shiny App to Implement Exact Methods

  2024cites this paper
• BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials

  2023cites this paper
• Exact sample size determination for a single Poisson random sample

  2023cites this paper
• Bayesian Sequential Monitoring of Single-Arm Trials: A Comparison of Futility Rules Based on Binary Data

  2021cites this paper
• Enhancing single-arm phase II trials by inclusion of matched control patients

  2020cites this paper
• Bayesian vs Frequentist Power Functions to Determine the Optimal Sample Size: Testing One Sample Binomial Proportion Using Exact Methods

  2017cites this paper